Home / Countries / France

WHO European Region · country profile

HIV, PrEP and sexual health access in France

France: 95% of verified HIV medicine records are reimbursed; PrEP is available and reimbursed; sexuality education is classified as progressive. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 02/11/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

Read more: HIV medicines in FrancePrEP in FranceDoxyPEP in FranceSexuality education in FranceAbortion and contraception rules in FranceHealthcare for migrants in France

HIV medicines95% reimbursed35 of 37 verified recordsPrEPReimbursed59,326 PrEP recipients (2024; UNAIDS GAM)DoxyPEPAvailable, not reimbursedNational access and guidanceSexuality educationProgressivePolicy frameworkFamily planning & abortionProgressiveAbortion law and contraceptionMigrant healthcare accessSuccessEntitlement and practice

5 HIV medicine records for France are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in France?

Of 37 verified HIV medicine records for France, 35 are available and reimbursed (95%), 0 are available but not reimbursed and 2 are not available. 5 further records are still under review.

Reimbursed 35

Apretude, Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Emtriva, Epivir, Eviplera, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress and 21 more

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in France?

Yes. In SHAPE's review, PrEP is available and reimbursed in France.

PrEP recipients: 59,326 PrEP recipients (2024; UNAIDS GAM)

UNAIDS GAM 2025 reports 59,326 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in France?

DoxyPEP can be accessed in France, but SHAPE's review did not find it reimbursed.

HAS recommends case-by-case DoxyPEP for multi-partner men who have sex with men and transgender women at high STI risk; universal reimbursement specifically for DoxyPEP was not verified. [Source: https://www.has-sante.fr/jcms/p_3586490/fr/doxycycline-en-prevention-des-infections-sexuellement-transmissibles-bacteriennes]

What is the policy on sexuality education in France?

SHAPE classifies the sexuality education framework in France as progressive. This describes the national policy framework, not how every school delivers it.

  • National framework: A national mandatory EVAR/EVARS curriculum took effect in the 2025–2026 school year, with at least three age-appropriate sessions annually and content on consent, equality, health and discrimination.
  • Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.education.gouv.fr/bo/2025/Hebdo6/MENE2503565C ; https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in France?

SHAPE classifies family planning and abortion rights in France as progressive, combining abortion law and contraception policy.

  • Abortion: Abortion is available on request through 14 weeks; the freedom to have an abortion was added to the Constitution in 2024.
  • Contraception: EPF's 2026 contraception-policy score is 97.9%; the atlas records broad national coverage.
  • Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/country/france/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in France?

SHAPE's editorial comparison places migrant healthcare access in France in the most accessible category (Success). Entitlement: Means-tested AME after residence period; urgent-care safety net.

Provider type: Public/social insurance system / AME / NGO · International migrants (2024): 9,186,757

  • Access rule: Undocumented low-income residents may qualify for State Medical Aid (AME) after more than three months of residence; urgent hospital care applies before eligibility in defined cases.
  • Main barriers: The waiting period, income and residence evidence, renewals and administrative complexity can interrupt access.
  • Migration measure: UN DESA estimates 9,186,757 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
  • Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
  • Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
  • Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Algeria (15.3%), Morocco (11.6%), Portugal (6.4%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 62.7%; Late HIV Diagnosis (CD4 <350, 2024): 38.3%

How France compares

France ranks #1 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (95%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

All HIV medicines in France

MedicineActive ingredientClassStatusEvidence and sourceChecked
Apretude
ViiV Healthcare
Cabotegravir (PrEP)INSTI (Long-Acting PrEP)ReimbursedReimbursed at 100% by national health insurance under a ministerial order of 18 February 2026, published in the Journal officiel on 26 February 2026 and effective from 2 March 2026 (price EUR 1,312.07 per injection). HAS opinion of 29 May 2024: SMR important, ASMR IV. [Sources: https://base-donnees-publique.medicaments.gouv.fr/medicament/62595850/extrait ; https://www.service-public.gouv.fr/particuliers/actualites/A18853?lang=en ; https://www.lemoniteurdespharmacies.fr/therapeutique/medicaments/fiches-medicaments/apretude-une-nouvelle-ere-pour-la-prep-en-france]02/11/2026
Biktarvy
Gilead Sciences
Bictegravir / Emtricitabine / TAFINSTI + NRTI/NtRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Celsentri
ViiV Healthcare
MaravirocEntry InhibitorReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Delstrigo
Merck
Doravirine / Lamivudine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Descovy
Gilead Sciences
Emtricitabine / TAFNRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Dovato
ViiV Healthcare
Dolutegravir / LamivudineINSTI + NRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Edurant
Janssen
RilpivirineNNRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Emtriva
Gilead Sciences
EmtricitabineNRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/61294762/extrait]02/11/2026
Epivir
ViiV Healthcare
LamivudineNRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/64777862/extrait]02/11/2026
Eviplera
Gilead Sciences
Rilpivirine / Emtricitabine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/63578537/extrait]02/11/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF)
Multiple (Generics)
Emtricitabine / Tenofovir DFNRTIReimbursedFully financed through the national health insurance framework. [Source: Santé publique France / HAS]14/09/2026
Genvoya
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / TAFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Intelence
Janssen
EtravirineNNRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Isentress
Merck
RaltegravirINSTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Juluca
ViiV Healthcare
Dolutegravir / RilpivirineINSTI + NNRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Kaletra
AbbVie
Lopinavir / RitonavirPIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Kivexa
ViiV Healthcare
Abacavir / LamivudineNRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual); renewal is unrestricted. Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69855489]02/11/2026
Norvir
AbbVie
RitonavirPI + pharmacokinetic enhancerReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=67851855]02/11/2026
Odefsey
Gilead Sciences
Rilpivirine / Emtricitabine / TAFNNRTI + NRTI/NtRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Pifeltro
Merck
DoravirineNNRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Prezista
Janssen
DarunavirPIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Rekambys
Janssen
RilpivirineLong-Acting NNRTIReimbursedLong-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing France record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Retrovir
ViiV Healthcare
ZidovudineNRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/63894243/extrait]02/11/2026
Reyataz
Bristol Myers Squibb
AtazanavirPIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/66745660/extrait]02/11/2026
Rukobia
ViiV Healthcare
FostemsavirAttachment InhibitorReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Stribild
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Reimbursed for treatment-naive adults; initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/65768058/extrait]02/11/2026
Sunlenca
Gilead Sciences
LenacapavirCapsid InhibitorReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Symtuza
Janssen
Darunavir / Cobicistat / Emtricitabine / TAFPI + NRTI/NtRTI + pharmacokinetic enhancerReimbursed100% covered by the French social security system (ALD 7) for eligible patients. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: Santé publique France / HAS; https://www.ema.europa.eu/en/medicines/human/variation/symtuza]14/09/2026
Tivicay
ViiV Healthcare
DolutegravirINSTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Triumeq
ViiV Healthcare
Dolutegravir / Abacavir / LamivudineINSTI + NRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Truvada
Gilead Sciences
Emtricitabine / Tenofovir DFNRTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. [Source: Santé publique France / HAS]14/09/2026
Viread
Gilead Sciences
Tenofovir DFNtRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/67279692/extrait]02/11/2026
Vocabria
ViiV Healthcare
CabotegravirINSTIReimbursed100% covered by the French social security system (ALD 7) for eligible patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Santé publique France / HAS; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Vocabria / Rekambys
ViiV Healthcare / Janssen
Cabotegravir / RilpivirineLong-Acting ARTReimbursedEMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Santé publique France / HAS; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]02/11/2026
Ziagen
ViiV Healthcare
AbacavirNRTIReimbursedListed in the French public medicines database as reimbursed at 100% by national health insurance. Initial prescription is reserved for hospital doctors (annual). Checked 2 November 2026. [Source: https://base-donnees-publique.medicaments.gouv.fr/medicament/68556562/extrait]02/11/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir)
Multiple (Generics)
Tenofovir DF / Lamivudine / DolutegravirINSTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Santé publique France / HAS]14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz)
Multiple (Generics)
Tenofovir DF / Lamivudine / EfavirenzNNRTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Santé publique France / HAS]14/09/2026
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris
Viatris Limited
Emtricitabine / Rilpivirine / Tenofovir alafenamideNNRTI + NRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris]14/09/2026
Emtricitabine / Tenofovir alafenamide Viatris
Viatris Limited
Emtricitabine / Tenofovir alafenamideNRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris]14/09/2026
Evotaz
Bristol Myers Squibb
Atazanavir / CobicistatPI + pharmacokinetic enhancerUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 13 July 2015. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz]14/09/2026
Rezolsta
Janssen
Darunavir / CobicistatPI + pharmacokinetic enhancerUnder reviewA fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta]14/09/2026
Yeytuo
Gilead Sciences
Lenacapavir (PrEP)Capsid Inhibitor (Long-Acting PrEP)Under reviewTwice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

Explore more

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.